A Secret Move Being Made By Top Biotech Leaders [NOW]
The top talent that helped build some of the most successful biotech organizations in the industry, quickly taking therapies to market, and who had a hand in major acquisitions are now part of the leadership team with roles like Chief Executive Officer and Chief Medical Officer at a company that already has a pipeline of novel drug therapies.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Reports Positive Results On Its Rare Blood Disorder
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is on its way into establishing a dominant position in a market, which is currently experiencing fierce competition. Following a pivotal Phase 3 study of the company’s ALXN1210, an experimental drug intended to treat a rare blood disorder there was no non-inferiority reported. The drug tested against and surprisingly, the study also revealed a non-inferiority on the four key secondary endpoints.